Indian Journal of PsychiatryIndian Journal of Psychiatry
Home | About us | Current Issue | Archives | Ahead of Print | Submission | Instructions | Subscribe | Advertise | Contact | Login 
    Users online: 1943 Small font sizeDefault font sizeIncrease font size Print this article Email this article Bookmark this page
Search Again
 Back
 Table of Contents
 
 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Article Access Statistics
 Reader Comments
 Email Alert
 Add to My List
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed826    
    Printed37    
    Emailed0    
    PDF Downloaded120    
    Comments [Add]    

Recommend this journal

 
ARTICLE
Year : 2002  |  Volume : 44  |  Issue : 3  |  Page : 260-265

A Comparative Study of the Efficacy and Safety of Mirtazapine Versus Amitriptyline in the Treatment of Major Depression


1 Professor & Head, Department of Psychiatry & Deaddiction Centre, J.L.N. Medical College & Hospital, Ajmer-305001, India
2 Associate Professor, Department of Psychiatry & Deaddiction Centre, J.L.N. Medical College & Hospital, Ajmer-305001, India
3 Assistant Professor, Department of Psychiatry & Deaddiction Centre, J.L.N. Medical College & Hospital, Ajmer-305001, India

Correspondence Address:
Anand Mathur
Professor & Head, Department of Psychiatry & Deaddiction Centre, J.L.N. Medical College & Hospital, Ajmer-305001
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 21206581

Rights and PermissionsRights and Permissions

A clinical trial was undertaken to evaluate the Anti depressant efficacy of Newer Antidepressant Mirtazapine in the treatment of major Depression in 39 patients in an O.P.D. setup. In addition to this clinical acceptability and safety profile of Mirtazapine as compared to that of Amitriptyline was also assessed. Mitazapine usually described as Noradrenergic and specific serotonergic Anti depressant (NaSSA). Patients aged 18-65 years who fulfilled the diagnostic criteria for a single or recurrent major Depressive disorder (as defined by DSM IV) for a minimum of 2 weeks were enrolled at our study centre. Patient assessment were conducted at screening, baseline, end of week 1, week 2, week 3, week 4, week 5 & end of week 6 for the efficacy & safety Parameters; HRSD, CGI, Adverse event follow up, BP & Pulse. Three level statistical analysis were performed on all efficacy measures including ANOVA (An Analysis of variance). The result indicates that mirtazapine is effective in the treatment of major depression at the dosages range of 15-45 mg/day and it has efficacy equivalent to that of the standard TCA Amitriptyline, albeit, with a substantially better tolerability profile.



[PDF]*

        

Print this article         Email this article